CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting

May 15, 2018

ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of the CRISPR team will make a series of presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held May 16-19, 2018 at the Hilton Chicago.

Title: Gene Editing Workshop
Presenter: Tirtha Chakraborty, Ph.D., Head of Hematology, CRISPR Therapeutics
Time and Date: Tuesday, May 15, 4:00 PM CT
Location: Hilton Chicago, Continental C

Title: Induction of HbF to Treat β-hemoglobinopathies – Bringing CRISPR to the Clinic
Presenter: Tony Ho, M.D., Head of Research and Development, CRISPR Therapeutics
Time and Date: Friday, May 18, 8:00 AM CT
Location: Hilton Chicago, International Ballroom North

Title: Allogeneic CAR T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9
Presenter: Melanie Allen, Scientist, CRISPR Therapeutics
Time and Date: Friday, May 18, 2018: 5:45 PM CT
Location: Hilton Chicago, P792, Stevens Salon C, D

Title: Efficient Clinical Scale CRISPR/Cas9-Mediated Editing of Plerixafor-Mobilized Hematopoietic Stem and Progenitor CD34+ Cells for Treatment of Sickle Cell Disease
Presenter: Hui Yu, Ph.D., Scientist, CRISPR Therapeutics
Time and Date: Saturday, May 19, 11:30 AM
Location: Hilton Chicago, Salon A-3,4

About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CONTACTS

CRISPR Therapeutics

MEDIA CONTACT:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com

INVESTOR CONTACT:
Chris Erdman
+1 617-307-7227 chris.erdman@crisprtx.com

Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 chris.brinzey@westwicke.com

Source: CRISPR Therapeutics AG